TECTB

Across TCGA pan-cancer cohorts, TECTB Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TECTB data layer compared with 19 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TECTB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TECTB expression acts as an unfavorable survival marker.

BLCA, LUAD, and ESCA are the cancer types where TECTB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.051	0.684	<.001	24	view →
LUAD	OS	Median	All	0.090	0.812	<.001	24	view →
ESCA	DFS	Median	II,III,IV	0.089	0.522	.001	12	view →
HNSC	OS	Median	All	0.389	0.689	.008	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TECTB–BLCA (OS)

Open the BLCA breakdown →